所在教研室/单位： 免疫学教研室

研究方向：长期以来从事分子病毒学和免疫学领域的研究

学习经历

2007.09.-2011.06. 本科学位 生物科学专业 生命科学学院 中山大学

2011.09.-2016.06. 博士研究生学位（硕博连读） 微生物学专业 博彩公司排名 中山大学

 

工作经历

2016.09.-2020.01. 博士后流动工作站 免疫学专业 博彩公司排名 中山大学

2020.02.-2023.04. 特聘正研究员 博彩公司排名 中山大学

2023.05.-                副教授 博彩公司排名 中山大学

 

个人简介

刘炳峰博士本科毕业于中山大学生命科学学院，于2016年获博彩公司排名-博彩公司评级 微生物博士学位。2016年至2023年在博彩公司排名-博彩公司评级 从事博士后和专职科研人员研究工作，并获得2017年中山大学优秀博士后称号。2023年起担任中山大学副教授职务。

长期以来从事分子病毒学和免疫学领域的研究，在治疗性T细胞免疫疗法清除HIV的病毒储存库方面取得了多项重要成果，并原创地研发了靶向HIV病毒储存库的bNAb-CAR-T免疫细胞疗法，申请并获得多项国家和PCT专利，并成功开展了清除病毒潜伏感染储存库的bNAb-CAR-T临床研究，对功能性治愈艾滋病具有重要的指导性意义。以第一作者或通讯作者身份发表在Journal of Clinical Investigation、Nature Communications、Signal Transduct Target Ther、mBio、Journal of Virology、Journal of Immunology、Frontiers in Immunology、Current Opinion in Virology、Cellular & Molecular Immunology杂志发表了多篇重要论文。主持了包括国家自然科学基金、“十三五”传染病重大专项子课题、广东省自然科学基金面上项目、中国博士后科学基金面上项目等多项研究。

 

第一作者或通讯作者发表文章

1.Zhang, Yiwen#; Li, Rong#; Li, Yuzhuang#; Yang, Hong; Zhou, Liqiong; Yuan, Jing; Pan, Ting; Liu, Bingfeng*; Zhang, Hui*; He, Yaqing*; Antibody response and cross-neutralization after Omicron BA.2 infection., Signal Transduction and Targeted Therapy, 2023

2.Zhang, Wanying#; Zhou, Mo; Chen, Cancan; Wu, Shiyu; Wang, Lilin; Xia, Baijin; Liu, Jun; Ma, Xiancai; Pan, Ting; Zhang, Hui; Li, Linghua; Liu, Bingfeng*; Identification of CD98 as a Novel Biomarker for HIV-1 Permissiveness and Latent Infection., mBio, 2022.

3.Liu, Bingfeng#; Zhang, Wanying; Xia, Baijin; Jing, Shuliang; Du, Yingying; Zou, Fan; Li, Rong; Lu, Lijuan; Chen, Shaozhen; Li, Yonghong; Hu, Qifei; Lin, Yingtong; Zhang, Yiwen; He, Zhangping; Zhang, Xu; Chen, Xiejie; Peng, Tao; Tang, Xiaoping; Cai, Weiping; Pan, Ting*; Li, Linghua*; Zhang, Hui*; Broadly neutralizing antibody-derived CAR-T cells reduce viral reservoir in HIV-1-infected individuals., Journal of Clinical Investigation, 2021.

4.Liu, Bingfeng#; Shi, Yaling#; Zhang, Wanying#; Li, Rong#; He, Zhangping; Yang, Xiaofan; Pan, Yuejun; Deng, Xilong; Tan, Mingkai; Zhao, Lingzhai; Zou, Fan; Zhang, Yiwen; Pan, Ting; Zhang, Junsong; Zhang, Xu; Xiao, Fei; Li, Fang*; Deng, Kai*; Zhang, Hui*; Recovered COVID-19 patients with recurrent viral RNA exhibit lower levels of anti-RBD antibodies., Cellular and Molecular Immunology, 2020, 17(10): 1098-1100. 

5.Zou, Fan#; Lu, Lijuan#; Liu, Jun; Xia, Baijin; Zhang, Wanying; Hu, Qifei; Liu, Weiwei; Zhang, Yiwen; Lin, Yingtong; Jing, Shuliang; Huang, Mei; Huang, Bifen; Liu, Bingfeng*; Zhang, Hui*; Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56., Nature Communications, 2019, 10(1): 4109. 

6.Liu, Bingfeng#; Zhang, Xu#; Zhang, Wanying; Wu, Liyang; Jing, Shuliang; Liu, Weiwei; Xia, Baijin; Zou, Fan; Lu, Lijuan; Ma, Xiancai; He, Dalian; Hu, Qifei; Zhang, Yiwen; Deng, Kai; Cai, Weiping; Tang, Xiaoping; Peng, Tao; Zhang, Hui*; Li, Linghua*; Lovastatin Inhibits HIV-1-Induced MHC-I Downregulation by Targeting Nef-AP-1 Complex Formation: A New Strategy to Boost Immune Eradication of HIV-1 Infected Cells., Frontiers in Immunology, 2019, 10: 2151.

7.Liu, Bingfeng#; Zhang, Wanying; Zhang, Hui*; Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir., Current Opinion in Virology, 2019, 38: 21-30. 

8.Zhang, Yiwen#; Liu, Weiwei; Chen, Yingshi; Liu, Jun; Wu, Kang; Su, Lishi; Zhang, Wanying; Jiang, Yawen; Zhang, Xu; Zhang, Yijun; Liu, Chao; Tao, Liang; Liu, Bingfeng*; Zhang, Hui*; A Cellular MicroRNA Facilitates Regulatory T Lymphocyte Development by Targeting the FOXP3 Promoter TATA-Box Motif., The Journal of Immunology, 2018, 200(3): 1053-1063. 

9.Liu, Bingfeng#; Zou, Fan#; Lu, Lijuan; Chen, Cancan; He, Dalian; Zhang, Xu; Tang, Xiaoping; Liu, Chao; Li, Linghua*; Zhang, Hui*; Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4( ) T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy, Journal of Virology, 2016, 90(21): 9712-9724. 

10.Geng, Guannan#; Liu, Bingfeng; Chen, Cancan; Wu, Kang; Liu, Jun; Zhang, Yijun; Pan, Ting; Li, Jun; Yin, Yue; Zhang, Junsong; Huang, Feng; Yu, Fei; Chen, Jingliang; Ma, Xiancai; Zhou, Jie; Kuang, Ersheng; Liu, Chao; Cai, Weiping; Zhang, Hui*; Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency, Molecular Therapy, 2016, 24(9): 1528-1537. 

 

主持科学项目

  1. 国家自然科学基金，青年科学基金项目：共表达抑制性受体shRNA的CAR-T细胞对重激活的HIV-1潜伏感染储存库清除作用的研究
  2. 十三五传染病重大专项，艾滋病精准诊治标志物的鉴定 子课题3 -不同疾病进程患者淋巴结组织中新型HIV-1潜伏感染细胞亚群的鉴定
  3. 广东省自然科学基金，面上项目：特异性敲除GSK3对CAR-T细胞长期生存和清除HIV-1病毒储存库的研究
  4. 中国博士后科学基金，面上项目：CAR-T细胞特异性清除再激活的HIV-1潜伏感染细胞

 

专利

  1. 张辉; 刘炳峰; 邹帆; 一种VC#CAR分子及在清除HIV#1感染细胞中的应用, 2016-08-10, 中国, CN201610652995.9. 
  2. VC-CAR molecule and use thereof in removing hiv-1 infected cell, United States Patent, Patent No: US 10,633,432 B2